Press Releases
-
Advanced BioDesign Publishes Groundbreaking Study in Cell Chemical Biology Introducing ABD-0171, a Next-Generation ALDH1 Inhibitor for Resistant Solid Tumors
Lyon, France – October 1st, 2025 – – Advanced BioDesign, a biotechnology company pioneering innovative cancer therapies through the inhibition of the aldehyde dehydrogenase, today…
-
Advanced BioDesign announces first patient treated under compassionate access for ABD-3001 in relapse and refractory T-cell cell acute lymphoblastic leukemia
Lyon (France), September 4th, 2025 – Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced that the…
-
Advanced BioDesign Announces Positive Interim Results from Phase 1 of the ODYSSEY Clinical Trial
Lyon (France), May 27, 2025 – Advanced BioDesign, a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic approaches for resistant cancers, today announced…
-
Advanced BioDesign to present preclinical proof of concept of ABD-0171 in MSS colorectal cancer at the AACR Annual Meeting 2025
Lyon, March 28th – Advanced BioDesign announced today it will present updated results of its second generation of ALDH1 inhibitor, ABD0171, at the upcoming AACR…
Advanced BioDesign 